Minghui and Qilu Pharmaceutical Unveil Promising MHB088C Data in mCRPC at ASCO 2026

Minghui and Qilu Pharmaceutical Unveil Promising MHB088C Data in mCRPC at ASCO 2026

Minghui Pharmaceutical and Qilu Pharmaceutical Co. have announced updated clinical data from their Phase I/II study of MHB088C (QLC5508) in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) at the 2026 ASCO Annual Meeting. The findings demonstrated encouraging anti-tumor activity and durable disease control. For BD teams and investors tracking the B7-H3 ADC space, the readout adds a new data point to an asset that's already generated a nine-figure Greater China licensing deal — and raises broader questions about Minghui's ex-China partnering strategy as the asset matures across multiple solid tumor indications.

Key Takeaways

• MHB088C (QLC5508) demonstrated encouraging anti-tumor activity in heavily pretreated mCRPC patients, a population with limited therapeutic options and poor prognosis.
• Durable disease control signals suggest the B7-H3 ADC may offer meaningful clinical benefit in later-line prostate cancer settings, where competition is intensifying.
• The data strengthens the overall profile of MHB088C across multiple tumor types, building on prior readouts in esophageal squamous cell carcinoma and extensive-stage small cell lung cancer.
• Qilu Pharmaceutical holds China rights under a deal worth up to $186M; Minghui retains ex-China rights, making this asset a potential outbound licensing candidate for Western or other international markets.

What Did the ASCO 2026 Data Show?

The updated Phase I/II results presented at ASCO 2026 focused on a cohort of heavily pretreated mCRPC patients — individuals who have typically exhausted standard-of-care options including novel hormonal agents and taxane-based chemotherapy. In this difficult-to-treat population, MHB088C showed encouraging anti-tumor activity, with responses that investigators characterized as clinically meaningful given the advanced disease stage of enrolled patients.

Durable disease control emerged as a particularly notable signal. For a heavily pretreated mCRPC cohort, maintaining disease stability over an extended period is itself a meaningful outcome, given the rapid progression typical of late-stage disease. The safety profile remained consistent with prior reports from the broader MHB088C program, which has now accumulated data across more than 300 patients in various solid tumor indications.

The mCRPC indication represents a strategically significant expansion for the B7-H3 ADC platform. Prostate cancer remains one of the highest-revenue oncology franchises globally, and the castration-resistant segment continues to attract substantial R&D investment. Demonstrating activity in this setting positions MHB088C alongside a growing field of ADCs and bispecifics targeting late-stage prostate cancer, though the B7-H3 target offers a differentiated mechanism that could appeal to partners seeking novel approaches.

What Is the Development History of MHB088C (QLC5508)?

MHB088C, also designated QLC5508, is a B7-H3-directed antibody-drug conjugate developed by Minghui Pharmaceutical, a late-stage clinical biopharmaceutical company focused on innovative oncology therapies. The drug targets B7-H3 (CD276), a member of the B7 immune checkpoint family that is overexpressed across multiple solid tumor types but has limited expression in normal tissue — making it an attractive target for ADC approaches.

The Phase I/II study presented at ASCO 2026 specifically enrolled patients with heavily pretreated mCRPC. Updated data from the trial showed that the drug maintained its previously observed safety profile while delivering anti-tumor signals in a population with significant unmet need. Prior data from the same program, including results presented at the 2024 ASCO Annual Meeting in patients with recurrent or metastatic solid tumors, had already established preliminary efficacy and tolerability benchmarks.

Minghui and Qilu Pharmaceutical entered into a strategic partnership and licensing agreement for MHB088C in Greater China. Under the terms, Qilu secured China rights for up to $186 million, a deal that signaled strong confidence in the asset's commercial potential within the region. Minghui retains development and commercialization rights outside Greater China, positioning it to pursue additional partnerships or direct development in Western markets.

The broader MHB088C clinical program spans multiple tumor types. At WCLC 2025, Qilu released Phase I data for QLC5508 in extensive-stage small cell lung cancer, adding another indication to the drug's development pipeline. A separate registrational study, NCT07463573, is evaluating QLC5508 versus chemotherapy in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, further diversifying the asset's clinical footprint. The FDA's Oncology Center of Excellence has been actively engaging with sponsors developing novel ADCs, and its guidance framework will likely inform any future registrational filings for assets like MHB088C in prostate cancer.

How Does MHB088C Fit Into the Competitive mCRPC Landscape?

Metastatic castration-resistant prostate cancer has become one of the most competitive indications in oncology. The approval of Pluvicto (lutetium-177-PSMA-617) opened the door for radiopharmaceutical approaches, while next-generation oral therapies and immunotherapies continue to enter late-stage development. Amid this crowded field, ADCs targeting novel antigens like B7-H3 offer a differentiated mechanism that could address patient populations who fail existing modalities.

The key differentiator for MHB088C is the durable disease control signal in heavily pretreated patients. Many competing agents show impressive response rates in earlier lines of therapy but lose efficacy as patients accumulate resistance mechanisms. An ADC that maintains disease control in later-line settings could fill a genuine gap in the treatment algorithm — and command a premium from partners or acquirers. ClinicalTrials.gov lists dozens of active interventional studies in mCRPC, underscoring both the commercial opportunity and the bar for differentiation.

What Are the Strategic and Commercial Implications?

The ASCO 2026 data update carries several layers of strategic significance. For BD teams monitoring the ADC space, MHB088C's expanding dataset across multiple indications — mCRPC, ES-SCLC, and ESCC — makes it a more attractive licensing target. Assets with broad tumor-agnostic potential command higher valuations, and the B7-H3 target's overexpression pattern across diverse cancers supports that thesis.

For Qilu, the mCRPC data reinforces the rationale behind its $186M China licensing commitment. Prostate cancer incidence in China is rising, and the domestic market for novel oncology therapies continues to expand as regulatory pathways mature and reimbursement coverage broadens. Positive data in mCRPC could accelerate Qilu's development timeline and strengthen its negotiating position with Chinese regulatory authorities.

Minghui faces a different calculus. With Qilu covering Greater China, Minghui's path to value realization runs through ex-China partnerships or independent development in Western markets. The mCRPC data is particularly relevant here: prostate cancer is a well-established, high-value indication in the US and Europe, and demonstrating activity in heavily pretreated patients could attract interest from large pharma companies seeking to complement their existing oncology portfolios. The company's prior ASCO 2024 presentation of Phase I/II monotherapy data in solid tumors laid the groundwork; the updated mCRPC cohort adds a disease-specific hook that dealmakers can work with.

Investors should watch for several near-term catalysts. The next clinical milestone for MHB088C in mCRPC will likely involve discussions with regulators about registrational trial design. If Minghui files an IND or initiates a pivotal study outside China, that would signal confidence in the data and potentially trigger partnership discussions. Qilu's progress in China — including any updates on its own regulatory filings — will also serve as a bellwether for the asset's commercial trajectory.

Frequently Asked Questions

Related coverage

• ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements
• BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors
• Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China